Albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
=== Ultimate Fighting Championship === On July 18, 2015, Casey debuted in the UFC to face The Ultimate Fighter: A Champion Will Be Crowned contestant Joanne Calderwood, at UFC Fight Night: Bisping vs. Leites, replacing the injured Bec Rawlings. After winning round one, Casey was outpointed by Calderwood in the next two rounds and lost a unanimous decision. Despite the loss, she was awarded a "Fight of the Night" bonus award. Casey next faced Seo Hee Ham at UFC Fight Night: Henderson vs. Masvidal on November 28, 2015. Again Casey lost a unanimous decision, but was awarded "Fight of the Night". Casey faced Cristina Stanciu at UFC Fight Night: McDonald vs. Lineker on July 13, 2016. She earned her first UFC win by defeating Stanciu by TKO in the first round. Casey next faced Randa Markos at UFC 202 on August 20, 2016. Casey caught Markos in an armbar, to which she verbally submitted, giving Casey back-to-back UFC wins. Casey next faced Cláudia Gadelha at UFC Fight Night: Bader vs. Nogueira 2. She lost the fight by unanimous decision. During the third round there was controversy when Gadelha appeared to land an illegal head kick on Casey while Casey was grounded. However, the referee deemed the kick unintentional and no point was deducted. A replay showed that Gadelha's shin appeared not to hit Casey's skull but caught her hair instead. Casey was criticized for allegedly trying to play up the illegal head kick and possibly achieve a disqualification win. Casey next faced Jessica Aguilar at UFC 211 on May 13, 2017. She won the fight via unanimous decision.
== Early life and education == Alessio Ciulli was born in Florence on 22 July 1977. He attended University of Florence in his hometown with an undergraduate laurea in chemistry and graduated magna cum laude. Under the late Prof Ivano Bertini, his final year laurea project was in computational drug design and NMR spectroscopy of matrix metalloproteases. Awarded with a Gates Cambridge Scholarship, he did his PhD under the supervision of the late Professor Chris Abell at the University of Cambridge and in collaboration with Astex Technology (now Astex Pharmaceuticals) produced a thesis concerned with studying weak protein-ligand interactions using biophysical and structural methods.
== Preceding viral infections == A number of different preceding viral infections have been reported, most commonly influenza A and B. The condition appears to be more prevalent during late fall, winter, and spring. Other virus infections that have been linked to BACM are those caused by Parainfluenza, Coxsackievirus, Adenovirus, Echovirus, and Mycoplasma pneumonia. Viral myositis after viral infections may also occur in adults, and viruses, such as COVID-19, have been reported as a rare cause of myositis.
Thrombocytopenia, i.e. can be associated with heparin-induced thrombocytopenia (0.5-5.0% of persons treated for at least five days) Elevations in serum aminotransferases: 5.9%-6.1% In people undergoing abdominal or colorectal surgery: Bleeding, anemia, ecchymosis: ≥ 2% In persons undergoing hip or knee replacement: Fever, nausea, anemia, edema, peripheral edema: ≥ 2% In persons with severely restricted mobility during acute illness: Dyspnea, thrombocytopenia, confusion, diarrhea, nausea: ≥ 2% In people being treated for deep vein thrombosis: Injection site hemorrhage, injection site pain, hematuria: ≥ 2% Frequency under investigation
Sources: en.wikipedia.org
In 1950, two Danish physicists Otto Kofoed-Hansen and Karl-Ove Nielsen discovered a new technique for producing radioisotopes which enabled production of isotopes with shorter half-lives than earlier methods. The Copenhagen experiment they carried out included a simplified version of the same elements used in modern on-line experiments. Ten years later, in Vienna, at a symposium about separating radioisotopes, plans for an 'on-line' isotope separator were published. Using these plans, CERN's Nuclear Chemistry Group (NCG) built a prototype on-line mass separator coupled to target and ion source, which was bombarded by a 600 MeV proton beam delivered by CERN's the Synchro-Cyclotron. The test was a success and showed that the SC was an ideal machine for on-line rare isotope production. The plan for an electromagnetic isotope separator was developed during 1963–4 by European nuclear physicists and, in late 1964, their proposal was accepted by the CERN Director-General and the ISOLDE project began.
3D bioprinting generally follows three steps: pre-bioprinting, bioprinting, and post-bioprinting. Pre-bioprinting is the process of creating a model that the printer will later create and choosing the materials that will be used. One of the first steps is to obtain a biopsy of the organ, to sample cells. Common technologies used for bioprinting are computed tomography (CT) and magnetic resonance imaging (MRI). To print with a layer-by-layer approach, tomographic reconstruction is done on the images. The now-2D images are then sent to the printer to be made. Once the image is created, certain cells are isolated and multiplied. These cells are then mixed with a special liquefied material that provides oxygen and other nutrients to keep them alive. This aggregation of cells does not require a scaffold, and is required for placing in the tubular-like tissue fusion for processes such as extrusion.
Caesium-135's predecessor xenon-135 is produced at a high rate of over 6% of fissions, but is an extremely potent absorber of thermal neutrons (neutron poison), so that most of it is transmuted to almost-stable xenon-136 before it can decay to caesium-135. If 90% of 135Xe is destroyed, then the remaining 135Cs's decay energy per unit time is initially only about 1% as great as that of the 99Tc. In a fast reactor, less of the Xe-135 may be destroyed.135Cs is the only alkaline or electropositive LLFP; in contrast, the main medium-lived fission products and the minor actinides other than neptunium are all alkaline and tend to stay together during reprocessing; with many reprocessing techniques such as salt solution or salt volatilization, 135Cs will also stay with this group, although some techniques such as high-temperature volatilization can separate it. Often the alkaline wastes are vitrified to form high level waste, which will include the 135Cs.Fission caesium contains not only 135Cs but also stable but neutron-absorbing 133Cs (which wastes neutrons and forms 134Cs which is radioactive with a half-life of 2 years) as well as the common fission product 137Cs which does not absorb neutrons but is highly radioactive, making handling more hazardous and complicated; for all these reasons, transmutation disposal of 135Cs would be more difficult. Palladium-107 has a very long half-life, a low yield (though the yield for plutonium fission is higher than the yield from uranium-235 fission), and very weak radiation.
At the start of 2016, experts warned the Philippines was at risk of having the Islamic State of Iraq and Syria (ISIS) set a foothold in the country. However, Duterte's predecessor, President Aquino III, dismissed the perpetrators of a March 2016 armed attack against the military as mere "mercenaries" wanting to join the ISIS. The earliest terrorist attacks in Duterte's presidency occurred in September 2016 in Davao City; November 2016 in Butig, Lanao del Sur; and in April to May 2017 in Inabanga, Bohol, where the Abu Sayyaf Group (ASG) attempted to establish a position in the Visayas. Though the military eventually quelled the sieges, the events were only a prelude to what would become Duterte's greatest challenge in combating terrorism.
== Products and pipeline == Glenmark's proprietary respiratory drug RYALTRIS, a nasal spray combining an antihistamine and a corticosteroid, received U.S. FDA approval for seasonal allergic rhinitis in adults and adolescents aged 12 and above. The company launched it in the United States in 2022. By 2026 it was available in 55 countries, and in July 2026 the FDA expanded approval to children aged 6 to under 12. The company's oncology portfolio consists mainly of licensed products. It distributes Tevimbra (tislelizumab) and Brukinsa (zanubrutinib) from BeiGene, and markets envafolimab as QiNHAYO in India and selected emerging markets under a license from Jiangsu Alphamab and 3D Medicines. In 2025 Glenmark also licensed trastuzumab rezetecan from Hengrui Pharma and aumolertinib from Hansoh Pharma. In dermatology, Winlevi (clascoterone cream) received European Commission approval for acne treatment in December 2025. Glenmark holds distribution rights in 17 European Union countries. For diabetes, Glenmark launched Lirafit, a liraglutide biosimilar, in January 2024, followed by Glipiq, a semaglutide biosimilar, in March 2026. Glenmark expanded its cardiovascular brand Telma (telmisartan), launched in 2003 for hypertension, to 16 related formulations. By 2024 the brand generated annual revenue of ₹1,036 crore.
Sources: en.wikipedia.org
Euthyroid sick syndrome (ESS) is a state of adaptation or dysregulation of thyrotropic feedback control wherein the levels of T3 or T4 are abnormal, but the thyroid gland does not appear to be dysfunctional. This condition may result from allostatic responses of hypothalamus-pituitary-thyroid feedback control, dyshomeostatic disorders, drug interferences, and impaired assay characteristics in critical illness. The classical phenotype of this condition is often seen in starvation, critical illness, or patients in the intensive care unit. Similar endocrine phenotypes are observed in fetal life and in hibernating mammals. The most common hormone pattern in nonthyroidal illness syndrome is low total and free T3, elevated rT3, and normal T4 and TSH levels, although T4 and TSH suppression may occur in more severe or chronic illness. This classical pattern results from type 1 allostatic load, i.e. a stress response resulting from lacking energy, oxygen, and glutathione. An alternative phenotype with a largely inverse hormonal pattern is seen in several physiological and pathological conditions, including pregnancy, obesity, endurance training, and psychiatric diseases. It is typically associated with high-T3 syndrome, increased plasma protein binding of thyroid hormones, and an elevated set point of the homeostatic system. It represents a response to type-2 allostatic load.
This should in no way suggest to clinicians or researchers that inhaled particles are not a greater threat than swallowed particles, it merely signifies that a combination of both methods may occur with some particles, no matter the size of or lipo/hydrophilicity of the different particle surfaces.
When placed in a nonchiral solvent like water, D-peptides, as well as the larger polypeptide D-proteins, have similar but mirrored properties to the L-peptides and L-proteins with identical sequences. If an L-protein does not require a chaperone or a structural cofactor to fold, its D-enantiomer protein should have a mirror image conformation with respect to the L-protein (Figure 2). A D-enzyme should act on substrates of reverse chirality compared to the L-enzyme with the same sequence. Similarly, if an L-peptide binds to an L-protein, their D-peptide and D-protein counterparts should bind together in a mirrored way. D-peptides also have properties that make them attractive as drugs. D-peptides are less susceptible to be degraded in the stomach or inside cells by proteolysis. D-peptide drugs can, therefore, be taken orally and are effective for a longer period of time. D-peptides are easy to synthesize when compared to many other drugs. In some cases, D-peptides can have a low immunogenic response.
=== Factors increasing cortisol levels === Viral infections increase cortisol levels through activation of the HPA axis by cytokines. Intense (high VO2 max) or prolonged aerobic exercise transiently increases cortisol levels to increase gluconeogenesis and maintain blood glucose; however, cortisol declines to normal levels after eating (i.e., restoring a neutral energy balance). Severe trauma or stressful events can elevate cortisol levels in the blood for prolonged periods. Low-carbohydrate diets cause a short-term increase in resting cortisol (≈3 weeks), and increase the cortisol response to aerobic exercise in the short- and long-term. Increase in the concentration of ghrelin, the hunger stimulating hormone, increases levels of cortisol.
=== Genome === The poppy genome contains 51,213 genes encoding proteins distributed 81.6% in 11 individual chromosomes and 18.4% remaining in unplaced scaffolds. In addition, 70.9% of the genome is made up of repetitive elements, of which the most represented are the long terminal repeat retrotransposons. This enrichment of genes is related to the maintenance of homeostasis and a positive regulation of transcription. The analysis of synergy of the opium poppy reveals traces of segmental duplications 110 million years ago (MYA), before the divergence between Papaveraceae and Ranunculaceae, and an event of duplication of the complete genome makes 7.8 MYA. The genes are possibly grouped as follows:
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.